Smith Grace L, Shlipak Michael G, Havranek Edward P, Masoudi Frederick A, McClellan William M, Foody JoAnne M, Rathore Saif S, Krumholz Harlan M
Section of Cardiovascular Medicine, Department of Internal Medicine, Yale University School of Medicine, New Haven, Conn 06520, USA.
Circulation. 2005 Mar 15;111(10):1270-7. doi: 10.1161/01.CIR.0000158131.78881.D5.
Renal impairment is an emerging prognostic indicator in heart failure (HF) patients. Despite known racial differences in the progression of both HF and renal disease, it is unclear whether the prognosis for renal impairment in HF patients differs by race. We sought to determine in HF patients the 1-year mortality risks associated with elevated creatinine and impaired estimated glomerular filtration rate (eGFR) and to quantify racial differences in mortality.
We retrospectively evaluated the National Heart Care Project nationally representative cohort of 53,640 Medicare patients hospitalized with HF. Among 5669 black patients, mean creatinine was 1.6+/-0.9 mg/dL, and 54% had an eGFR < or =60, compared with creatinine 1.5+/-0.7 mg/dL and 68% eGFR < or =60 in 47,971 white patients. Higher creatinine predicted increased mortality risk, although the magnitude of risk differed by race (interaction P=0.0001). Every increase in creatinine of 0.5 mg/dL was associated with a >10% increased risk in adjusted mortality for blacks, compared with >15% increased risk in whites (interaction P=0.0001), with the most striking racial disparities at the highest levels of renal impairment. Depressed eGFR showed similar racial differences (interaction P=0.0001).
Impaired renal function predicts increased mortality in elderly HF patients, although risks are more pronounced in whites. Distinct morbidity and mortality burdens in black versus white patients underscore the importance of improving patient risk-stratification, defining optimal therapies, and exploring physiological underpinnings of racial differences.
肾功能损害是心力衰竭(HF)患者中一个新出现的预后指标。尽管已知HF和肾脏疾病进展存在种族差异,但尚不清楚HF患者肾功能损害的预后是否因种族而异。我们试图确定HF患者中与肌酐升高和估计肾小球滤过率(eGFR)受损相关的1年死亡风险,并量化死亡率的种族差异。
我们回顾性评估了全国心脏护理项目中具有全国代表性的53640例因HF住院的医疗保险患者队列。在5669例黑人患者中,平均肌酐为1.6±0.9mg/dL,54%的患者eGFR≤60,而在47971例白人患者中,肌酐为1.5±0.7mg/dL,68%的患者eGFR≤60。较高的肌酐水平预示着死亡风险增加,尽管风险程度因种族而异(交互作用P=0.0001)。肌酐每增加0.5mg/dL,黑人调整后死亡率风险增加超过10%,而白人增加超过15%(交互作用P=0.0001),在肾功能损害最严重的水平上种族差异最为显著。eGFR降低也显示出类似的种族差异(交互作用P=0.0001)。
肾功能受损预示老年HF患者死亡率增加,尽管白人的风险更为明显。黑人和白人患者不同的发病和死亡负担凸显了改善患者风险分层、确定最佳治疗方法以及探索种族差异生理基础的重要性。